Last reviewed · How we verify
HPV+MMR（0d），HPV（6m）
This is a sequential immunization regimen combining HPV and MMR vaccines to provide protection against human papillomavirus and measles, mumps, and rubella through adaptive immune response.
This is a sequential immunization regimen combining HPV and MMR vaccines to provide protection against human papillomavirus and measles, mumps, and rubella through adaptive immune response. Used for Prevention of human papillomavirus-related cancers and precancerous lesions, Prevention of measles, mumps, and rubella.
At a glance
| Generic name | HPV+MMR（0d），HPV（6m） |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The regimen administers an HPV vaccine at baseline (day 0) simultaneously with MMR vaccine, followed by a second HPV vaccine dose at 6 months. HPV vaccine stimulates antibody production against HPV capsid proteins to prevent cervical and other HPV-related cancers, while MMR vaccine provides live attenuated viral immunity against measles, mumps, and rubella. The staggered HPV dosing allows for optimal antibody titers while MMR provides concurrent protection against three viral diseases.
Approved indications
- Prevention of human papillomavirus-related cancers and precancerous lesions
- Prevention of measles, mumps, and rubella
Common side effects
- Injection site pain, swelling, or erythema
- Fever
- Myalgia or arthralgia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: